Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 10 of 15

 
 

Revolution Medicines (NASDAQ:RVMD)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$54.00 (8.5% Upside)

About Revolution Medicines

Revolution Medicines logoRevolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00 ➝ $61.00
9/27/2024BarclaysBoost Price TargetOverweight ➝ Overweight$54.00 ➝ $60.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$56.00 ➝ $56.00
8/8/2024JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $54.00
8/8/2024WedbushReiterated RatingOutperform ➝ Outperform$59.00 ➝ $59.00
8/8/2024Needham & Company LLCLower Price TargetBuy ➝ Buy$62.00 ➝ $61.00
7/18/2024BarclaysBoost Price TargetOverweight ➝ Overweight$52.00 ➝ $54.00
7/16/2024OppenheimerBoost Price TargetOutperform ➝ Outperform$45.00 ➝ $55.00
7/16/2024Bank of AmericaBoost Price TargetBuy ➝ Buy$48.00 ➝ $55.00
7/16/2024Needham & Company LLCBoost Price TargetBuy ➝ Buy$46.00 ➝ $62.00
 

Musk’s new company could top a trillion? (Ad)

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.